Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IntReALL HR 2010
2012-000810-12Phase 2
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Feb 2016
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of bortezomib in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: CR2 rate after randomized induction.
02
Drugs
bortezomib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2012-000810-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000810-12.